GlaxoSmithKline UK

Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com
Summary of Product Characteristics last updated on the eMC: 13/07/2007
SPC Alkeran Tablets 2mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 13/07/2007 and displayed until Current
Reasons for adding or updating:
  • Change to section 5.2 - Pharmacokinetic Properties
Date of revision of text on the SPC:   07/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 5.2

An update to the information provided regarding the experience of melphalan in the elderly. Updated information under headings absorption, distribution and metabolism.

Updated on 28/06/2007 and displayed until 13/07/2007
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   05/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.1: Removal of indication: adjuvant to surgery in management of breast cancer
Section 4.4: Update leukaemogenic wording
Section 4.8: Update to add Anaemia undesirable effect & MedDRA frequencies and wording
Section 4.9: Deletion of neutropenia and addition of leucopoenia and anaemia
Section 10: 17/05/2007
Updated on 14/03/2005 and displayed until 28/06/2007
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
Updated on 22/04/2003 and displayed until 14/03/2005
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Updated on 19/12/2002 and displayed until 22/04/2003
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 16/12/2002 and displayed until 19/12/2002
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 12/12/2002 and displayed until 16/12/2002
Reasons for adding or updating:
  • Change to section 10 (date of (partial) revision of the text
Updated on 13/07/2001 and displayed until 12/12/2002
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.8 - Undesirable Effects
Updated on 12/04/2000 and displayed until 13/07/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   melphalan


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk